EBS News and Press, Emergent Biosolutions Inc. From 06/27/20

Vaccine startup Vaxart (NASDAQ: VXRT) announced Thursday morning that it was initiating a memorandum of understanding with Attwill Medical Solutions Sterilflow. The latter company will produce components for Vaxart's COVID-19 vaccine candidate currently in preclinical development, and Vaxart...

I last covered Emergent BioSolutions ( EBS ) in July 2018 . Since then, much has changed for the world and the overall pharmaceutical industry. The stock has managed to swoop right past my target price and is now trading at new highs. In fact, this small life sciences company with a special...

Emergent BioSolutions (NYSE: EBS ) will invest $75M in its Canton, Massachusetts facility, focused on the development and manufacturing of drug substance for live viral vaccines and plans to expand into viral vector and gene therapy. More news on: Emergent BioSolutions Inc., Healthc...

Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing facility to increase campus footprint and build out advanced therapy capability Advanced therapy CDMO drug substance manufacturing services expected to be available begi...

People who had COVID-19 and are now fully recovered may be eligible to donate plasma to help patients currently infected with COVID-19. Their plasma likely contains antibodies that bind and inhibit SARS-CoV-2, the novel coronavirus that causes COVID-19. The American Red Cross requires donors...

Many companies have shifted into high gear to address the multiple needs related to the COVID-19 pandemic. Two at the forefront of these efforts are OPKO Health (NASDAQ: OPK) and Emergent BioSolutions (NYSE: EBS) . Both OPKO and Emergent have delivered tremendous stock performances so fa...

AstraZeneca (NYSE: AZN ) will work with Emergent Biosolutions (NYSE: EBS ) to help produce the 300M doses of ADZ1222 that AZN has pledged to the U.S. More news on: AstraZeneca PLC, Emergent BioSolutions Inc., Healthcare stocks news, Read more ...

Small-cap Emergent BioSolutions (NYSE: EBS) has landed another contract to manufacture a possible COVID-19 vaccine, this time with European pharmaceutical giant AstraZeneca . Of course, the contract, said to be worth as much as $87 million, hinges on whether AstraZeneca's vaccine gets appro...

Emergent Biosolutions ( EBS +0.1% ) seeks to deploy its molecule-to-market contract development and manufacturing services through 2020 to support the manufacturing of AstraZeneca’s (NYSE: AZN ) vaccine candidate for COVID-19, AZD1222, for ~$87M. More news on: Emergent ...

Emergent will provide contract development and manufacturing services and secure large-scale manufacturing capacity through 2020 to support AstraZeneca’s COVID-19 vaccine candidate Agreement valued at approximately $87 million GAITHERSBURG, Md., June 11, 2020 (GLOBE NEWSWIRE) --...